Impact renaming non-alcoholic fatty liver disease to metabolic associated fatty liver disease in prevalence, characteristics and risk factors DOI Open Access
Xinjuan Huang,

Man Yin,

Bingqian Zhou

et al.

World Journal of Hepatology, Journal Year: 2023, Volume and Issue: 15(8), P. 985 - 1000

Published: Aug. 22, 2023

Recently, a group of hepatologists proposed to rename non-alcoholic fatty liver disease (NAFLD) as metabolic associated (MAFLD) with modified diagnostic criteria. It is important note, however, that there are some differences between the criteria used for NAFLD and MAFLD. Since research on MAFLD just beginning, evidence its incidence prevalence in general population specific subpopulations remains limited.To assess epidemiology new definition compare NAFLD. Exploring risk factors individuals.This was retrospective, cross-sectional study. A total 85242 adults were selected from Chinese health management database 2017-2022. The data information, laboratory indicators, lifestyle psychological status obtained. diagnosed ultrasound diagnosis at least one these three conditions: Overweight/obesity, type 2 diabetes mellitus (T2DM) or dysregulation. Metabolic not considered standard. clinical characteristics analysed using descriptive statistics. Continuous variables normally distributed expressed means ± SD. Categorical frequencies proportions. Binary logistic regression determine MAFLD.The 40.5% 31.0%, respectively. more likely be older (M: 47.19 10.82 vs 43.43 11.96; N: 47.72 11.17 43.71 11.66), male 77.21% 44.43%; 67.90% 53.12%) high body mass index 26.79 2.69 22.44 2.48; 26.29 2.84 23.29 3.12) than non-MAFLD population. In multivariate analysis, information (e.g., ≥ abnormalities OR = 3.38, (95%CI: 2.99-3.81), P < 0.001; diastolic blood pressure 1.01, 1.00-1.01), 0.002), results [e.g.,total bilirubin (TBIL) 0.98, 0.98-0.99), serum uric acid(SUA) 1.01-1.01), 0.001], [e.g., drink beverage 0.32, 0.17-0.63), 0.001] influence Our study offer insight into potential disease, including SUA, TBIL creatinine, all which related chronic renal (CKD).MAFLD prevalent NAFLD, two-fifths individuals meeting populations have different characteristics. CKD may

Language: Английский

Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention DOI Creative Commons
Xiaodong Zhou, Jingjing Cai, Giovanni Targher

et al.

Cardiovascular Diabetology, Journal Year: 2022, Volume and Issue: 21(1)

Published: Dec. 3, 2022

The newly proposed term "metabolic dysfunction-associated fatty liver disease" (MAFLD) is replacing the old "non-alcoholic (NAFLD) in many global regions, because it better reflects pathophysiology and cardiometabolic implications of this common disease. change terminology from NAFLD to MAFLD not simply a single-letter an acronym, since defined by set specific positive diagnostic criteria. In particular, definition specifically incorporates within classification recognized cardiovascular risk factors. Although convincing evidence supports significant association between both MAFLD, with increased CVD morbidity mortality, neither nor have received sufficient attention Cardiology community. fact, there paucity scientific guidelines focusing on burdensome disease professional societies. This Perspective article discusses rationale clinical relevance for Cardiologists definition.

Language: Английский

Citations

100
An international multidisciplinary consensus statement on MAFLD and the risk of CVD DOI Open Access
Xiaodong Zhou, Giovanni Targher, Christopher D. Byrne

et al.

Hepatology International, Journal Year: 2023, Volume and Issue: 17(4), P. 773 - 791

Published: May 19, 2023

Language: Английский

Citations

91
From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications DOI Creative Commons
Andrea Boccatonda,

Lorenzo Andreetto,

Damiano D’Ardes

et al.

Biomedicines, Journal Year: 2023, Volume and Issue: 11(3), P. 883 - 883

Published: March 13, 2023

Non-alcoholic fatty liver disease (NAFLD) is defined as a chronic characterized by excessive fat accumulation in the without another obvious cause (no alcohol consumption, hepatotoxic medications, toxins, viral infections, genetic hepatic diseases), therefore it an exclusion diagnosis. The term NAFLD literally refers to non-alcohol related hepatopathy and does not adequately correlate with metabolic dysfunction cardiovascular risks. Therefore, researchers scientific societies have moved towards changing terminology. novel nomenclature for metabolic-associated (MAFLD) has been proposed 2020 group of experts overcome issues old diagnosis MAFLD based on presence steatosis at least one between these three conditions: type 2 diabetes mellitus (T2DM), obesity or dysregulation. shown be independent risk factor diseases atherosclerosis. It better main factors atherosclerosis than NAFLD, such dyslipidemia, T2DM hypertension. aim this review highlight reasons why moving MAFLD, what are conceptual basis choice its clinical implications, particularly field.

Language: Английский

Citations

65
MAFLD predicts cardiovascular disease risk better than MASLD DOI
Ziyan Pan, Gamal Shiha, Gamal Esmat

et al.

Liver International, Journal Year: 2024, Volume and Issue: 44(7), P. 1567 - 1574

Published: April 20, 2024

Abstract Background and Aim Metabolic dysfunction‐associated steatotic liver disease (MASLD) has been proposed as an alternative for the validated definition of metabolic fatty (MAFLD). We compared abilities MAFLD MASLD to predict risk atherosclerotic cardiovascular (ASCVD). Methods Six thousand ninety six participants from 2017 2020 National Health Nutrition Examination Survey cohort who received a thorough medical health check‐up were chosen study. The associations between status coronary surrogates, such 10‐year ASCVD self‐reported events, analysed. Results identified in 2911 (47.7%) 2758 (45.2%) patients, respectively. (odds ratio [OR]: 2.14, 95% confidence interval [CI], 1.78–2.57, p < .001) was more strongly independently associated with high than (OR: 1.82, CI, 1.52–2.18, comparison absence each condition. However, MAFLD, alone not increased risk. Multiple logistic regression revealed that significantly 2.82; CI: 1.13–7.01; .03) alone. Conclusions Although both different risks, predicted better MASLD. higher predictive ability attributed dysfunction rather moderate alcohol use.

Language: Английский

Citations

36
Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up DOI
Hun Jee Choe, Joon Ho Moon, Won Kim

et al.

Metabolism, Journal Year: 2024, Volume and Issue: unknown, P. 155800 - 155800

Published: Jan. 1, 2024

Language: Английский

Citations

27
Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis DOI Creative Commons
Limin Cao, Yu An, Huiyuan Liu

et al.

BMC Medicine, Journal Year: 2024, Volume and Issue: 22(1)

Published: March 6, 2024

Abstract Background Non-alcoholic fatty liver disease (NAFLD) and metabolic-associated (MAFLD) shares common pathophysiological mechanisms with type 2 diabetes, making them significant risk factors for diabetes. The present study aimed to assess the epidemiological feature of diabetes in patients NAFLD or MAFLD at global levels. Methods Published studies were searched terms that included using PubMed, EMBASE, MEDLINE, Web Science databases from their inception December 2022. pooled regional prevalence incidence density evaluated random-effects meta-analysis. Potential sources heterogeneity investigated stratified meta-analysis meta-regression. Results A total 395 (6,878,568 participants NAFLD; 1,172,637 MAFLD) 40 countries areas among was 28.3% (95% confidence interval 25.2–31.6%) 26.2% (23.9–28.6%) globally. 24.6 per 1000-person year (20.7 29.2) 26.9 (7.3 44.4), respectively. Conclusions describes MAFLD. findings serve as a valuable resource clinical economic impact

Language: Английский

Citations

26
Cardiovascular disease and metabolic dysfunction-associated steatotic liver disease: pathophysiology and diagnostic aspects DOI Creative Commons
Søren Møller, Nina Kimer, Jens D. Hove

et al.

European Journal of Preventive Cardiology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 27, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) can be interpreted as the hepatic expression of metabolic syndrome, which is estimated to affect 30% adult population. Obesity, dyslipidaemia, arterial hypertension, and T2DM are considered significant risk factors MASLD. The relationship two-way with MASLD found in up 75% patients T2DM. Importantly, associated increased cardiovascular diseases (CVD) such arrhythmia, atherosclerotic heart disease, failure, CVD-associated mortality. In addition, present a high prevalence major adverse cardiac events, calls for systematic surveillance CVD This review focuses on pathophysiology behind development MASLD, types complications, morbidity survival, suggestions evaluation

Language: Английский

Citations

2
Cardiovascular morbidity and mortality in lean vs. non-lean MASLD: A comprehensive meta-analysis DOI
Nso Nso, Damla Mergen, Mashaal Ikram

et al.

Current Problems in Cardiology, Journal Year: 2024, Volume and Issue: 49(6), P. 102569 - 102569

Published: April 8, 2024

Language: Английский

Citations

12
The Pathophysiological Associations Between Obesity, NAFLD, and Atherosclerotic Cardiovascular Diseases DOI

Meng Li,

Man Cui,

Guoxia Li

et al.

Hormone and Metabolic Research, Journal Year: 2024, Volume and Issue: 56(10), P. 683 - 696

Published: March 12, 2024

Abstract Obesity, non-alcoholic fatty liver disease (NAFLD), and atherosclerotic cardiovascular diseases are common growing public health concerns. Previous epidemiological studies unfolded the robust correlation between obesity, NAFLD, diseases. Obesity is a well-known risk factor for both of them can markedly increase odds On other hand, significant weight loss achieved by lifestyle modification, bariatric surgery, or medications, such as semaglutide, concomitantly improve NAFLD Therefore, certain pathophysiological links involved in development obesity NAFLD. Moreover, recent indicated that simultaneously targeting several mechanisms tirzepatide retatrutide leads to greater improves complications metabolic syndrome. These findings remind importance mechanistic viewpoint breaking association In this review article, we mainly focus on shared mechanisms, including insulin resistance, dyslipidemia, GLP1 signaling, inflammation, oxidative stress, mitochondrial dysfunction, gut dysbiosis, renin-angiotensin-aldosterone system (RAAS) overactivity, endothelial dysfunction. Most these alterations primarily initiated obesity. The further exacerbates molecular cellular alterations, leading progression final manifestation perturbation. A better insight into makes it feasible develop new multi-target approaches unhinge deleterious chain events linking

Language: Английский

Citations

11
Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes DOI Creative Commons
Karl Vaz, Daniel Clayton‐Chubb, Ammar Majeed

et al.

Hepatology International, Journal Year: 2023, Volume and Issue: 17(5), P. 1082 - 1097

Published: Aug. 9, 2023

For the first time in nearly half a century, fatty liver disease has undergone change name and definition, from exclusive term, non-alcoholic (NAFLD), to inclusion-based, metabolic-associated (MAFLD). This led investigators across globe evaluate impact nomenclature had on epidemiology natural history of disease.

Language: Английский

Citations

22